ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (1541.HK)
HKD 7.1
(10.94%)
HKD 7.1
(10.94%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 424.65 Thousand CNY | -21.07% |
| 2022 | 538 Thousand CNY | -89.38% |
| 2021 | 5.06 Million CNY | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 389.62 Thousand HKD | -90.67% |
| 2024 Q2 | 386.29 Thousand HKD | -0.15% |
| 2023 Q4 | 4.26 Million HKD | 2.57% |
| 2023 FY | 424.65 Thousand CNY | -21.07% |
| 2023 Q3 | 4.15 Million HKD | 8845.1% |
| 2023 Q2 | 46.43 Thousand HKD | -5.52% |
| 2023 Q1 | 49.15 Thousand HKD | -98.35% |
| 2022 FY | 538 Thousand CNY | -89.38% |
| 2022 Q4 | 2.97 Million HKD | 2.58% |
| 2022 Q3 | 2.9 Million HKD | 465.95% |
| 2022 Q2 | 513.19 Thousand HKD | 0.0% |
| 2021 FY | 5.06 Million CNY | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Uni-Bio Science Group Limited | 392.81 Million HKD | 99.892% |
| CK Life Sciences Int'l., (Holdings) Inc. | 947.7 Million HKD | 99.955% |